REGENXBIO (NASDAQ:RGNX) Earns “Buy” Rating from Chardan Capital

REGENXBIO (NASDAQ:RGNX)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They currently have a $52.00 price target on the biotechnology company’s stock.

Several other equities analysts also recently commented on the company. Morgan Stanley boosted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target for the company. HC Wainwright reduced their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

REGENXBIO Trading Up 9.0 %

NASDAQ RGNX opened at $8.50 on Thursday. REGENXBIO has a 12 month low of $5.62 and a 12 month high of $23.14. The stock has a market cap of $421.13 million, a price-to-earnings ratio of -1.69 and a beta of 1.35. The company’s 50 day moving average is $7.28 and its two-hundred day moving average is $8.93.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. Sell-side analysts forecast that REGENXBIO will post -4.84 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. FMR LLC lifted its stake in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. GAMMA Investing LLC increased its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of REGENXBIO in the fourth quarter valued at $54,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of REGENXBIO in the 4th quarter worth about $79,000. Finally, Laurion Capital Management LP purchased a new position in shares of REGENXBIO during the 4th quarter worth about $79,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.